Sign in
Taking people in United StatesNo phase

Studying heart failure subtypes using imaging, blood data and health records

Studies heart failure in adults 30 years and older to find subtypes for personalized care.

Key facts

Who runs it
Northwestern University
Where
Boston, Chicago, Philadelphia, Rochester, Sacramento, and Winston-Salem, United StatesSee the 6 sites
Trial code
Registry title
HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets
Status
Recruiting
People taking part
1,000 people, planned
Started
1 Mar 2023
Expected to end
Dec 2028
Type of study
Observational, 2 groups
Record updated
29 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 30 or older with heart failure, including heart failure with a preserved ejection fraction, and for people without heart failure as comparison groups.

Age
30 years or older
Sex
All sexes can join.
Disease stage
Heart failure (any ejection fraction) for the registry. For the deep phenotyping group: heart failure with preserved ejection fraction (HFpEF), ejection fraction 50% or higher, NYHA class II-IV, with at least one sign such as high BNP or NTproBNP, a past hospital stay for heart failure, high wedge pressure, or a high H2FPEF or HFA-PEFF score of 5 or more.
Earlier treatment
Comparison groups must have no past heart failure diagnosis and no loop diuretic use (registry) or no diuretic use for fluid (deep phenotyping).
Biomarker or test result
HFpEF group: BNP 75 pg/ml or higher, or NTproBNP 225 pg/ml or higher (higher cut-offs apply in atrial fibrillation or flutter). Comparison group in the deep phenotyping cohort: BNP below 75 pg/ml or NTproBNP below 225 pg/ml.

Main reasons for not taking part

  • Past solid organ transplant
  • Past mechanical circulatory support or non-cardiac cirrhosis
  • Currently on dialysis or eGFR below 20 ml/min/1.73m2
  • Currently pregnant
  • Cannot give written consent

The registry criteria, word for word

Show all 37 criteriaShow less

Who can take part

  • HF Inclusion Criteria (HeartShare Registry)
  • Age ≥30 years
  • Prior diagnosis of HF in the EHR (any left ventricular ejection fraction); Non-HF Group Inclusion Criteria (HeartShare Registry)
  • Age ≥30 years
  • No known prior diagnosis of HF or use of loop diuretics
  • No known prior history of BNP >100 pg/ml or NTproBNP >300 pg/ml, if prior laboratory tests are available in the EHR; HFpEF Inclusion Criteria (HeartShare Deep Phenotyping Cohort)
  • Age ≥30 years
  • Left ventricular ejection fraction ≥50% measured by echocardiography
  • Definition of HFpEF: signs and symptoms of HF, NYHA functional class II-IV, and at least one of the following:; Elevated BNP (≥75 pg/ml in sinus rhythm or ≥225 pg/ml in atrial fibrillation/flutter) or NTproBNP (≥225 pg/ml in sinus rhythm or ≥675 in atrial fibrillation/flutter) at baseline. Choice of BNP or NTproBNP is based on availability at each clinical center; Prior HF hospitalization (primary reason for the hospitalization is HF with elevated natriuretic peptide levels [using the thresholds listed above], requiring IV diuresis for HF, or pulmonary edema or pulmonary vascular congestion on chest radiography); Elevated pulmonary capillary wedge pressure (PCWP) at rest (≥15 mmHg) or during exercise (≥25 mmHg for supine exercise or PCWP/cardiac output ratio ≥2 mmHg/L/min for upright exercise); Elevated H2FPEF score26 (≥5) or HFA-PEFF27 score (≥5); Non-HFpEF Group Inclusion Criteria (HeartShare Deep Phenotyping Cohort)
  • Age ≥30 years
  • Left ventricular ejection fraction ≥50% measured by echocardiography
  • No known prior diagnosis of HF or use of diuretics for fluid management
  • No known prior history of BNP ≥75 pg/ml or NTproBNP ≥225 pg/ml, if prior laboratory tests are available in the EHR
  • BNP <75 pg/ml or NTproBNP <225 pg/ml at the time of screening. Choice of BNP or NTproBNP is based on availability at each clinical center

Who cannot take part

  • Prior history of solid organ transplantation
  • Prior history of mechanical circulatory support
  • Prior history of non-cardiac cirrhosis
  • Cardiac surgery, acute coronary syndrome, percutaneous coronary intervention, stroke, transient ischemic attack, or carotid intervention in the preceding 6 months prior to enrollment
  • Prior history of solid organ transplantation
  • Prior history of chronic infection (HIV, hepatitis C, hepatitis B, tuberculosis) unless treated and not clinically active in the opinion of the enrolling investigator
  • Prior history of mechanical circulatory support
  • Prior history of non-cardiac cirrhosis
  • Primary cardiomyopathy (including amyloid, hypertrophic cardiomyopathy, cardiac sarcoidosis, hemochromatosis, or other infiltrative cardiomyopathies) or pulmonary arterial hypertension (WHO Group I, III, or IV pulmonary hypertension)
  • Clinically significant valvular heart disease defined as:; Moderate to greater aortic stenosis, pulmonic stenosis, or tricuspid stenosis; Any mitral stenosis; Moderate or greater aortic regurgitation; Greater than moderate mitral regurgitation
  • Any planned cardiac surgery or cardiac intervention in the next 3 months
  • Known symptomatic epicardial coronary artery disease that is not revascularized
  • Any condition that may preclude participation or adherence to the study protocol, in the opinion of the enrolling investigator
  • Current acute decompensated heart failure
  • For non-HF group: any prior known left ventricular ejection fraction <50%
  • Any prior known left ventricular ejection fraction <40%, except if this occurred only in the setting of an acute tachycardia episode (e.g., acute atrial fibrillation)
  • Estimated GFR <20 ml/min/1.73m2 or currently on dialysis
  • Inability to provide written consent to the study
  • Life expectancy estimated to be < 1 year
  • Alternative primary reason for symptoms of shortness of breath and exercise intolerance in HFpEF participants in the opinion of the enrolling investigator
  • Any non-elective hospitalization in the preceding 2 weeks
  • Inability to provide written consent to the study
  • Currently pregnant

Where in United States

  • Mass General BrighamBoston, United StatesContact: Diane Cocca-SpoffordNot yet recruiting
  • Northwestern UniversityChicago, United StatesContact: Laura AlagnaTaking people
  • University of PennsylvaniaPhiladelphia, United StatesContact: Tiffany SharkoskiTaking people
  • Mayo ClinicRochester, United StatesContact: Matthew AdolphsenTaking people
  • University of California - DavisSacramento, United StatesContact: Maiya HerTaking people
  • Wake Forest UniversityWinston-Salem, United StatesContact: Ben NelsonNot yet recruiting

About the trial

What the trial wants to find out

HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes to help develop more personalized treatments for patients, with the hope that this will improve the lives of heart failure patients. To do this, HeartShare is bringing together a large amount of data (including images, such as heart ultrasounds and MRIs and molecular data from the blood, such as genetics) from previously conducted studies and electronic health records, and is gathering new data through participants enrolled in the HeartShare Deep Phenotyping Study.

The 2 groups in the trial

  • HFpEF

    Participants with HFpEF

  • Non-HFpEF

    Participants without HFpEF

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
HeartShare Deep Phenotyping Study
Plain-language title
Studying heart failure subtypes using imaging, blood data and health recordsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
29 September 2026